

PRESS RELEASE

Company Release – 1/5/18 7:00AM EST



ARTICULUS BIO TO PRESENT AT 10TH ANNUAL BIOTECH SHOWCASE CONFERENCE DURING JPM HEALTHCARE WEEK

BOULDER, CO, January 5, 2018 (GLOBE NEWSWIRE) – Articulus Bio, LLC, a development-stage orthopedic medical device platform focused on total joint replacement, today announced that Adam B. Rubenstein, Chief Executive Officer, will present at the 10th annual Biotech Showcase Conference on Wednesday, January 10, 2018, at 3:15 p.m. PST. The conference is being held at the Hilton Union Square Hotel in San Francisco, California.

The presentation will be webcast live and may be accessed by visiting the “Investors & Media” section of the Company’s website at www.articulusbio.com. A replay of the webcast will be available for 90 days.

About Articulus Bio, LLC

Articulus Bio, LLC is a development-stage orthopedic medical device platform focused on total joint replacement. Our novel Tendonoid™ Web Joint technology addresses the problem at the heart of total joint replacement failures: polyethylene particulate wear debris. In vivo degradation of prosthetic implant materials is increasingly recognized as a major factor limiting the durability of total joint arthroplasty. The poly-wear shedding occurs at articulating faces of the appliances caused by grinding, sliding and friction from natural anatomical motion. An immunological cascade is catalyzed by the wear particles that stimulates osteolysis, an adverse local host response, leading to periprosthetic bone loss that compromises implant fixation and bone stock, typically ending in device failure. The Articulus Bio Tendonoid™ Web Joint technology engineers out the friction inducing grinding and sliding thereby eliminating wear debris. In addition, personalized 3D print geometries, customized jigs, individualized ranges of motion, and proven surfacing techniques contribute to improved bone/device bond integrity, reduced bone/blood loss, improved surgical positioning and decreased OR time. Pipeline product candidates include total ankle replacement device and cervical/lumbar spine artificial discs. For more information please visit www.articulusbio.com.

Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, including statements regarding Articulus Bio’s strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management or the expected features of or potential indications for Articulus Bio’s product candidates are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could

PRESS RELEASE

Company Release – 1/5/18 7:00AM EST



differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation: that Articulus Bio has incurred losses since its inception, and anticipates that it will continue to incur significant losses for the foreseeable future; future financing activities may cause Articulus Bio to restrict its operations or require it to relinquish rights; Articulus Bio may fail to demonstrate safety and efficacy of its product candidates; Articulus Bio's product candidates are unproven and may never lead to marketable products; Articulus Bio's product candidates are based on a relatively novel technology, which makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval, if at all; Articulus Bio's product candidates may cause undesirable side effects or have other properties that could delay or prevent regulatory approval; and the results of Articulus Bio's work to date are not sufficient to show safety and efficacy of Articulus Bio's product candidates and may not be indicative of future results. Articulus Bio has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Moreover, Articulus Bio operates in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for its management to predict all risks, nor can it assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements it may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Articulus Bio undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.

Investor/Media Contact:

Robin Olson

everettAbbott

(303) 902-4413

info@everettAbbott.com